Our Pricing

Does Wegovy Work For Everyone? Understanding Individual Response and Effectiveness

Does Wegovy work for everyone seeking weight loss? While semaglutide (Wegovy) demonstrates impressive efficacy in clinical trials, individual response varies significantly based on adherence, metabolic factors, and underlying health conditions. Our UK-registered clinical team at Cured Pharmacy has supported thousands of patients through their weight loss journey, and we've observed that success depends on multiple factors beyond simply taking the injection.

Does Wegovy Work For Everyone: What Clinical Trials Tell Us

The STEP clinical trial programme provides robust evidence on whether Wegovy works for everyone. In the pivotal STEP 1 trial, participants achieved an average weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. However, this average masks significant individual variation — approximately 86% of participants lost at least 5% of their body weight, whilst 69% achieved 10% or more weight loss.

This data reveals an important truth: Wegovy does not work equally for everyone. Around 14% of trial participants did not achieve clinically meaningful weight loss (defined as ≥5% body weight reduction) [1]. Factors influencing response included baseline insulin resistance, adherence to the dosing schedule, concurrent lifestyle modifications, and individual metabolic differences. Our superintendent pharmacist Tarun Kumar notes that patients who combine Wegovy with structured dietary changes typically see superior outcomes compared to those relying on medication alone.

Who Cannot Take Wegovy: Does Wegovy Work For Everyone With Obesity?

Wegovy is not suitable for everyone, regardless of weight loss goals. The medication is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or known hypersensitivity to semaglutide [2]. Additionally, it should not be used during pregnancy or by individuals with a history of severe gastrointestinal disease, including inflammatory bowel disease or gastroparesis.

Even among eligible patients, does Wegovy work for everyone equally? Evidence suggests differential response rates. Patients with type 2 diabetes may experience slightly different outcomes compared to those without diabetes — the STEP 2 trial showed 9.6% average weight loss in diabetic participants versus 14.9% in the general obesity population [2]. Age, sex, baseline BMI, and ethnicity also influence response, though Wegovy demonstrates efficacy across diverse demographic groups when prescribed appropriately by a UK-registered prescriber.

Wegovy Eligibility Criteria in the UK

UK prescribing guidelines specify Wegovy for adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia. All prescription requests at Cured Pharmacy undergo clinical assessment to ensure suitability, with treatment starting from £69.00 subject to prescriber approval.

Does Wegovy Work For Everyone Compared to Mounjaro: Effectiveness Analysis

When patients ask does Wegovy work for everyone versus Mounjaro (tirzepatide), head-to-head comparison data provides clarity. While no direct randomised controlled trial has compared the two medications, cross-trial analysis suggests tirzepatide may produce greater average weight loss. The SURMOUNT-1 trial showed participants on the highest tirzepatide dose (15mg) achieved 20.9% average weight loss, compared to 14.9% with semaglutide 2.4mg in STEP 1 [3].

However, does Wegovy work for everyone less effectively than Mounjaro? The answer is nuanced. Tirzepatide's dual GIP/GLP-1 receptor agonism may offer advantages for some patients, particularly those with significant insulin resistance or who have plateaued on GLP-1 agonists alone [3]. Conversely, Wegovy's longer clinical track record, established safety profile, and lower starting price (from £69.00 versus £69.00 for Mounjaro) make it the preferred first-line option for many UK patients. Individual response remains the critical determinant — some patients respond exceptionally to semaglutide, whilst others may benefit from switching to tirzepatide if initial results are suboptimal.

Does Wegovy Work For Everyone: Factors Predicting Individual Response

Several biological and behavioural factors determine whether Wegovy works optimally for an individual patient. Genetic variations in GLP-1 receptor expression, baseline insulin sensitivity, gut microbiome composition, and concurrent medications all influence semaglutide efficacy [4]. Patients with higher baseline insulin resistance often require longer treatment duration to achieve comparable weight loss to metabolically healthier individuals.

Adherence represents the single most modifiable predictor of success. Does Wegovy work for everyone who takes it inconsistently? Clinical evidence demonstrates that patients missing doses or discontinuing treatment prematurely experience significantly reduced outcomes [4]. At Cured Pharmacy, our UK-registered clinical team emphasises the importance of the full dose escalation schedule — starting at 0.25mg weekly and gradually increasing to the maintenance dose of 2.4mg over 16-20 weeks minimises gastrointestinal side effects and optimises long-term adherence.

Optimising Wegovy Response Through Lifestyle Integration

Combining Wegovy with a reduced-calorie diet and increased physical activity significantly enhances outcomes. Participants in the STEP trials who received intensive behavioural therapy alongside semaglutide achieved greater weight loss than those on medication alone, suggesting that does Wegovy work for everyone depends substantially on comprehensive lifestyle modification rather than pharmacotherapy in isolation.

Does Wegovy Work For Everyone: Managing Non-Response and Treatment Alternatives

For the minority of patients who do not achieve adequate weight loss with Wegovy, does Wegovy work for everyone or are alternatives needed? NICE guidance recommends discontinuing GLP-1 receptor agonists if patients fail to lose at least 5% body weight after 6 months at the therapeutic dose [5]. In such cases, switching to tirzepatide (Mounjaro), which offers dual incretin activity, represents a logical next step given its superior average weight loss in clinical trials.

Other patients may benefit from combination approaches or different medication classes. Orlistat (from £69.00), Mysimba (from £69.00), or Saxenda (liraglutide, from £69.00) offer alternative mechanisms of action for those unsuitable for or unresponsive to semaglutide [5]. Our superintendent pharmacist Tarun Kumar conducts thorough medication reviews to identify optimal alternatives when Wegovy does not produce expected results, ensuring every patient receives personalised treatment aligned with their metabolic profile and weight loss goals.

Does Wegovy Work For Everyone: Real-World Evidence from UK Clinical Practice

Real-world data from UK prescribing practices provides additional context beyond controlled trials. Observational studies suggest that whilst clinical trial efficacy may not fully translate to routine practice due to lower adherence rates and less intensive lifestyle support, Wegovy still produces meaningful weight loss for the majority of patients [6]. Average real-world weight loss typically ranges from 10-12%, slightly below trial outcomes but still clinically significant.

Does Wegovy work for everyone in UK pharmacy settings? Our experience at Cured Pharmacy mirrors published evidence — approximately 75-80% of patients who complete the full dose escalation and maintain treatment for at least 6 months achieve ≥5% weight loss, with around 50-60% reaching ≥10% reduction. Patients benefit from transparent upfront pricing (from £69.00), discreet packaging, and ongoing support from our UK-registered clinical team. All treatments require online clinical assessment by a qualified prescriber, with same-day approval available for eligible patients and next-day delivery across the UK.

Accessing Wegovy at the Cheapest UK Price

Cured Pharmacy offers Wegovy from £69.00 with an additional £20 off your first order using code Weightlossnew, representing the cheapest UK price for genuine licensed medication. Our GPhC-registered pharmacy (9012511) ensures all treatments meet MHRA standards, with prescriptions issued only after thorough clinical assessment to confirm suitability and safety.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (Clinical guideline CG189). [accessed 15 August 2026]
6. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. [accessed 15 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.